# Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

> **NCT00289536** · PHASE4 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 38 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Antihemophilic factor, recombinant, manufactured protein-free
- **BIOLOGICAL:** Antihemophilic factor, recombinant, manufactured protein-free
- **BIOLOGICAL:** Antihemophilic factor, recombinant, manufactured protein-free

## Key facts

- **NCT ID:** NCT00289536
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02-02
- **Primary completion:** 2007-04-01
- **Final completion:** 2007-04-01
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00289536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00289536, "Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00289536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*